Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

  • Awaiting development
  • GID-TA11686
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Camizestrant with palbociclib within its marketing authorisation for treating untreated oestrogen receptor-positive HER2-negative metastatic breast cancer